Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...
Pfizer Inc. has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Despite skepticism over Pfizer's recent acquisitions, Metsera's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results